The Market Signal was created as a platform to help investors, if you own (NASDAQ:EDUC), (NYSE:PTGX) or (NASDAQ:PSTI) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.
https://themarketsignal.com/Free-Report/NOW
(Click link above or copy, paste and hit enter in your browser for your report)
Educational Development Corporation is bullish following renewal of its credit line
https://themarketsignal.com/Free-Report/EDUC
(Click link above or copy, paste and hit enter in your browser for your report)
Educational Development Corporation (NASDAQ:EDUC) has gained 184.49% over the past six months.
Educational Development Corporation has renewed its credit line with its first lender MidFirst Bank, for another year. This is according to a statement by Educational Development Corporation CEO Randall White. The credit comes with a maximum principal amount of $10,000,000.
According to Mr. White, the credit line has been secured thanks to the company's strong position and credit rating. He noted that the company recently reported an increase in cash flow. The company closed the quarter with $23.3 million in cash.
Protagonist Therapeutics is bullish on a strong cash position
https://themarketsignal.com/Free-Report/PTGX
(Click link above or copy, paste and hit enter in your browser for your report)
Protagonist Therapeutics Inc (NASDAQ:PTGX) has gained 181.57% over the past six months.
Protagonist Therapeutics has announced raising $105.7 million from an underwriting and offering of 8,050,000 shares at $14.00 per share. The company issued a total of 1.2 million shares during the second quarter of 2020. The shares were issued through the company's at-the-market (ATM) program and were priced at $14.02 per share. The company raised $16.8 million from the offering.
Pluristem Therapeutics is bullish following approval of its COVID-19 vaccine trial
https://themarketsignal.com/Free-Report/PSTI
(Click link above or copy, paste and hit enter in your browser for your report)
Pluristem Therapeutics Inc. (NASDAQ:PSTI) has gained 178.03% over the past six months.
Pluristem Therapeutics has announced that its Phase II clinical protocol for its study titled, "A Randomized, Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of severe COVID-19." has been cleared by Germany's health regulatory agency, the Paul Ehrlich Institute (PEI). The company will enrol 40 patients with severe cases of COVID-19 in the study.
Please email or contact us for any edits or errors relating to this stock market news.
If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.
We will get back to you within 24 hours.
COMTEX_370623698/2700/2020-09-03T06:44:02
Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.
